Drugs / NeuroAiD
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00554723 | May 2007 → Aug 2012 | cerebral infarction | CHIMES Society | Completed | Missed primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT02537899 | Apr 2015 → Sep 2023 | spinal cord injury | Moleac Pte Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00721825 Comparator | Jan → Jul 2008 | cerebral infarction | Moleac Pte Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 12
| Date | Issuer | Release |
|---|---|---|
| 2025-08-11 | Moleac Pte Ltd. | Results 𝗔𝗦𝗡𝗔 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 | 𝗕𝗮𝗹𝗶, 𝗜𝗻𝗱𝗼𝗻𝗲𝘀𝗶𝗮 | 𝟴 – 𝟭𝟬 𝗔𝘂𝗴𝘂𝘀𝘁 𝟮𝟬𝟮𝟱 moleac.com ↗
The presentation summarized multiple clinical trials on NeuroAiD, reinforcing its role in post-stroke motor recovery and fostering valuable discussions with stroke care experts. |
| 2025-06-26 | Moleac Pte Ltd. | Results 🧠 NeuroAiD™II Shows Promising Results in Spinal Cord Injury Preclinical Study moleac.com ↗
NeuroAiD™II (MLC901) administration led to marked improvements in motor and sensory function, enhanced nerve conduction, axonal regeneration, and tissue preservation. |
| 2024-10-11 | Moleac Pte Ltd. | Results STROKE STUDY HIGHLIGHTS: Cost-Effectiveness of NeuroAiD in Post-Stroke Recovery – Insights from CHIMES & CHIMES-E Studies moleac.com ↗
Key findings reveal: 💰Potential cost-savings of €5,080 and a gain of 0.45 QALYs. |
| 2024-06-24 | Moleac Pte Ltd. | Results Exploring Breakthroughs in Alzheimer’s Treatment: An Interview with Prof Christopher Chen on the ATHENE Trial moleac.com ↗
This study provides evidence for the use of NeuroAiD as an add-on to standard Alzheimer’s Disease treatment. |
| 2024-05-27 | Moleac Pte Ltd. | Results Discover the Impact of NeuroAiD on Stroke Recovery: Insights from Dr. N Venketasubramanian moleac.com ↗
Their findings indicate that patients receiving NeuroAiD achieved functional recovery significantly faster compared to those on placebo. |
| 2022-06-08 | Moleac Pte Ltd. | Results NeuroAiD has shown favourable outcome in patients suffering from spinal cord injuries moleac.com ↗
NeuroAiD was safe as add-on treatment in patients with severe SCI. |
| 2022-03-08 | Moleac Pte Ltd. | Results Prognostic Factors and Pattern of Long-Term Recovery with MLC601 (NeuroAiD™) in the Chinese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study moleac.com ↗
At 12 months NeuroAiD almost doubles the chances of achieving functional independence. |
| 2022-03-08 | Moleac Pte Ltd. | Results NeuroAiD™II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression moleac.com ↗
NeuroAiD™II showed long-term safety as an add-on therapy in AD with no increase of patients experiencing either serious adverse events or adverse events. |
| 2022-03-08 | Moleac Pte Ltd. | Results NeuroAiD™ has shown persistent long-term benefits after an initial 3-month treatment following stroke onset moleac.com ↗
This study has showed that NeuroAiD™ increases significantly the odds of achieving functional independence at 6 months which persisted up to 18 months after stroke, as measured by the mRS. |
| 2022-03-08 | Moleac Pte Ltd. | Results NeuroAiD combined with rehabilitation has shown additive and sustained benefits on post-stroke recovery over 2 years after an initial 3-month treatment following stroke onset moleac.com ↗
More subjects on NeuroAiD™ improved to functional independence compared to placebo among subjects receiving rehabilitation up to 3 months after an acute ischemic stroke. |
| 2022-03-08 | Moleac Pte Ltd. | Results Highlights from Asia Pacific Stroke Organization (APSC) and World Congress of Neurology (WCN) Scientific Symposia moleac.com ↗
Professor Chen commented that “it is spectacular that even a 3-month treatment can (translate to) such long-term benefit, and highlighted that “in patients who do not have such a good prognosis, NeuroAiD ™ enhances recovery and more patients gradually improved to full independence (mRS 0 – 1) and they stayed there”. |
| 2022-03-08 | Moleac Pte Ltd. | Results Chinese Herbal Medicine May Have Delayed Benefit in Stroke moleac.com ↗
Long-term follow-up of a trial investigating a Chinese herbal supplement in patients with stroke suggests there may be some benefit after 6 to 18 months. |
All press releases naming this drug 34 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NeuroAiD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02537899 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “a Traditional Chinese Medicine NeuroAid” NCT00721825 ↗ |